Bluebird Bio expects delay on FDA sickle cell drug application
The goal of submitting lovo-cel for US market clearance by the end of March is beginning to look unobtainable.
By Angelica Peebles, bloomberg
Bluebird Bio Inc. expects to fall short of its goal to seek regulatory approval for its sickle cell gene therapy by the end of March, the latest setback for the struggling biotechnology company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk completes Forma Therapeutics acquisition
For subscribers
